BioScrip Reports First Quarter 2013 Financial Results

ELMSFORD, N.Y., May 8, 2013 /PRNewswire/ -- BioScrip, Inc. (NASDAQ: BIOS) today announced 2013 first quarter financial results.  First quarter revenue from continuing operations was $199.1 million and the net loss from continuing operations was $7.5 million, or $0.13 per diluted share. Consolidated Adjusted EBITDA for the first quarter was $11.5 million, and consolidated Adjusted EPS for the first quarter was $0.04 per diluted share.

(Logo: http://photos.prnewswire.com/prnh/20130117/NY44138LOGO )

As a result of the sale of the Company's traditional and specialty pharmacy mail operations and community retail pharmacy stores on May 4, 2012 (the "Pharmacy Services Asset Sale"), the Company's financial statements reflect the discontinued operations' results for the three months ended March 31, 2013 and 2012 separate from the continuing operations of the business. The remaining assets and liabilities of the divested business that were not transferred as a part of the Pharmacy Services Asset Sale are included in continuing operations.  

First Quarter Highlights

  • Revenue from continuing operations increased by $43.4 million, or 27.9%, as compared to the prior year. Revenue from our Infusion Services segment increased by $45.3 million, or 41.5% as compared to the prior year;
  • Gross profit from continuing operations increased 18.1% to $63.2 million, or 31.8% of revenue, from $53.5 million, or 34.4% of revenue, in the prior year period;
  • Adjusted EBITDA from continuing operations increased $3.1 million, or 37.0% to $11.5 million, or 5.8% of revenue, from $8.4 million, or 5.4% in the prior year period.  The performance in the quarter included investments in growth initiatives, such as increased sales resources and the development of new market offerings;
  • Acquired HomeChoice Partners, Inc. ("HomeChoice"), formerly a majority-owned subsidiary of DaVita HealthCare Partners Inc. (NYSE: DVA); and
  • Initiated a review of the Company's capital structure to support its growth strategy.

"We are pleased to report another quarter of solid performance.  Our results reflect the continued execution of our strategic plan, growing organically and targeting opportunistic acquisitions that enable us to expand our national infusion footprint. Our site of service initiatives are providing us with increased access to patient census and the opportunity for continued growth as patient care moves to lower-cost settings, such as the home or alternate sites of administration," said Rick Smith, President and Chief Executive Officer of BioScrip.

Results of Operations

First Quarter 2013 versus First Quarter 2012
Revenue from continuing operations for the first quarter of 2013 totaled $199.1 million, compared to $155.6 million for the same period a year ago, an increase of $43.4 million or 27.9%.  Infusion Services segment revenue was $154.4 million in the first quarter, as compared to $109.1 million for the same period in 2012.  The 41.5% increase was driven primarily by overall volume growth as well as additional revenue related to acquisitions.  Home Health Services segment revenue was $17.9 million for the first quarter of 2013, as compared to $16.7 million in the prior year quarter.  The 7.4% increase was primarily the result of growth in volume from private duty nursing activity.  PBM Services segment revenue was $26.8 million for the first quarter of 2013, compared to $29.9 million for the prior year period.  The decrease was due primarily to a reduction in discount card volume.

Consolidated gross profit for the first quarter of 2013 was $63.2 million, or 31.8% of revenue, compared to $53.5 million, or 34.4% of revenue, for the first quarter of 2012.  The increase in gross profit was the result of growth in Infusion Services segment revenues.  The decline in gross profit margin percentage was mainly the result of business mix.

During the first quarter of 2013, Infusion Services Segment Adjusted EBITDA was $12.3 million, or 8.0% of segment revenue, compared to $7.8 million, or 7.1% of segment revenue in the prior year quarter.

The Home Health Services Segment Adjusted EBITDA in the first quarter of 2013 was $883,000, or 4.9% of segment revenue, compared to $1.1 million, or 6.5% of segment revenue, in the comparable prior year period. 

The PBM Services Segment Adjusted EBITDA was $6.2 million, or 23.2% of segment revenue, for the first quarter of 2013 compared to $6.1 million, or 20.4% of segment revenue, in the prior year quarter.

On a consolidated basis, BioScrip reported $11.5 million of Adjusted EBITDA during the first quarter of 2013, or 5.8% of total revenue, compared to $8.4 million, or 5.4% of total revenue, in the same period last year.  The performance in the quarter included investments in growth initiatives, such as increased sales resources and the development of new market offerings.

Interest expense in the first quarter of 2013 was $6.5 million compared to $6.6 million in the prior year period.

Income tax expense for continuing operations in the first quarter was $58,000 compared to an income tax benefit of $502,000 in the first quarter of 2012.

Net loss from continuing operations for the first quarter of 2013 was $7.5 million, or a loss of $0.13 per diluted share, compared to a net loss of $2.0 million, or $0.04 per diluted share, for the first quarter of 2012.  Adjusted EPS from continuing operations for the first quarter of 2013 was $0.04 per diluted share, compared to Adjusted EPS from continuing operations of $0.00 per diluted share, for the first quarter of 2012.

Liquidity and Capital Resources
The Company's cash balance at the end of the first quarter was zero and outstanding borrowings under its revolving credit facility was approximately $28.0 million as it utilized a combination of its available cash and borrowings under its revolving credit facility to fund the acquisition of HomeChoice.  Subsequent to the end of the first quarter, the Company raised net proceeds of $118.6 million from a public offering of its common stock and used part of such net proceeds to pay down outstanding amounts under its revolving credit facility.

Outlook
The Company reaffirms its initial 2013 revenue target of $830.0 million to $865.0 million and 2013 Adjusted EBITDA target of $67.0 million to $73.0 million.

Conference Call
BioScrip will host a conference call to discuss its first quarter 2013 financial results on May 9, 2013 at 8:30 a.m. Eastern Time.

Interested parties may participate in the conference call by dialing 800-705-5308 (US), or 303-223-4377 (International), 5-10 minutes prior to the start of the call. A replay of the conference call will be available for two weeks after the call's completion by dialing 800-633-8284 (US) or 402-977-9140 (International) and entering conference call ID number 21656383. An audio webcast and archive will also be available for 30 days under the "Investor Relations" section of the BioScrip website at www.bioscrip.com.

About BioScrip, Inc.
BioScrip, Inc. provides comprehensive infusion and home care solutions. By partnering with patients, physicians, healthcare payors, government agencies and pharmaceutical manufacturers we are able to provide access to infusible medications and management solutions. Our goal is to optimize outcomes for chronic and other complex healthcare conditions and enhance the quality of patient life. BioScrip brings clinical competence in providing high-touch, comprehensive infusion and nursing services to patients in the most convenient ways possible. Through our customer services and treatments we aim to ensure the best possible therapy outcome.

Forward Looking Statements – Safe Harbor

This press release includes statements that may constitute "forward-looking statements," including projections of certain measures of the Company's results of operations, projections of certain charges and expenses, and other statements regarding the Company's goals, regulatory approvals and strategy.  These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  You can identify these statements by the fact that they do not relate strictly to historical or current facts.  In some cases, forward-looking statements can be identified by words such as "may," "should," "could," "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," "predict," "potential," "continue"  or comparable terms.  Investors are cautioned that any such forward-looking statements are not guarantees of future performance and, because such statements inherently involve risks and uncertainties, actual results may differ materially from those in the forward-looking statements. Factors that could cause or contribute to such differences include but are not limited to risks associated with: the Company's ability to grow its Infusion Services segment organically or through acquisitions and obtain financing in connection therewith; its ability to effectively integrate acquisitions; its ability to reduce operating costs while sustaining growth; reductions in federal, state and commercial payor reimbursement for the Company's products and services; increased government regulation related to the health care and insurance industries; as well as the risks described in the Company's periodic filings with the Securities and Exchange Commission, including the Company's annual report on Form 10-K for the year ended December 31, 2012.  The Company does not undertake any duty to update these forward-looking statements after the date hereof, even though the Company's situation may change in the future.  All of the forward-looking statements herein are qualified by these cautionary statements.

Reconciliation to Non-GAAP Financial Measures

In addition to reporting all financial information required in accordance with generally accepted accounting principles ("GAAP"), the Company is also reporting EBITDA, Adjusted EBITDA, and Adjusted EPS, which are non-GAAP financial measures. EBITDA, Adjusted EBITDA and Adjusted EPS are not measurements of financial performance under GAAP and should not be used in isolation or as a substitute or alternative to net income, operating income or any other performance measure derived in accordance with GAAP, or as a substitute or alternative to cash flow from operating activities or a measure of our liquidity. In addition, the Company's definitions of EBITDA, Adjusted EBITDA and Adjusted EPS may not be comparable to similarly titled non-GAAP financial measures reported by other companies.  EBITDA represents net income before net interest expense, income tax expense, depreciation and amortization.  Adjusted EBITDA, as defined by the Company, represents net income before net interest expense, income tax expense, depreciation and amortization, stock-based compensation expense, acquisition and integration expenses, and restructuring and other expenses. As part of restructuring and other expenses, the Company may incur significant charges such as, but not limited to, the write down of certain long−lived assets, temporary redundant expenses, retraining expenses, potential cash bonus payments and potential accelerated payments or terminated costs for certain of its contractual obligations. Adjusted EPS, as defined by the Company, represents earnings per diluted share, excluding the same elements in calculating Adjusted EBITDA (restructuring and other expenses, acquisition and integration expenses, stock-based compensation expense) as well as the impact of acquisition-related intangible amortization.  Management believes that these non-GAAP financial measures provide useful supplemental information regarding the performance of our business operations and facilitates comparisons to our historical operating results. For a full reconciliation of EBITDA, Adjusted EBITDA and Adjusted EPS to the most comparable GAAP financial measures, please see the attachments to this earnings release. 

(Financial Tables Follow)

 

Schedule 1

BIOSCRIP, INC





CONSOLIDATED BALANCE SHEETS

(in thousands, except for share amounts)






March 31,

2013


December 31,

2012

ASSETS




Current assets




Cash and cash equivalents

$                  -


$           62,101

Receivables, less allowance for doubtful accounts of $21,482 and $22,728 at

December 31, 2012 and December 31, 2011, respectively

158,127


129,103

Inventory

22,819


34,034

Prepaid expenses and other current assets

9,081


10,189

Total current assets

190,027


235,427

Property and equipment, net

27,767


23,721

Goodwill

414,234


350,810

Intangible assets, net

19,364


17,446

Deferred financing costs

2,522


2,877

Investments in and advances to unconsolidated affiliate

10,415


10,042

Other non-current assets

1,385


2,053

Total assets

$        665,714


642,376

LIABILITIES AND STOCKHOLDERS' EQUITY




Current liabilities




Current portion of long-term debt

$          27,992


953

Accounts payable

32,108


34,438

Claims payable

7,599


7,411

Amounts due to plan sponsors

16,303


18,173

Accrued interest

11,575


5,803

Accrued expenses and other current liabilities

37,580


41,491

Total current liabilities

133,157


108,269

Long-term debt, net of current portion

225,372


225,426

Deferred taxes

10,748


10,291

Other non-current liabilities

8,971


4,981

Total liabilities

378,248


348,967

Stockholders' equity




Preferred stock, $.0001 par value; 5,000,000 shares authorized; no shares issued or

outstanding


Common stock, $.0001 par value; 125,000,000 shares authorized; shares issued:

59,695,646 and 59,600,713, respectively; shares outstanding: 57,113,126 and

57,026,957, respectively

6


6

Treasury stock, shares at cost: 2,582,520 and 2,582,520, respectively

(10,311)


(10,311)

Additional paid-in capital

390,983


388,798

Accumulated deficit

(93,212)


(85,084)

Total stockholders' equity

287,466


293,409

Total liabilities and stockholders' equity

$        665,714


$         642,376


Schedule 2

BIOSCRIP, INC





CONSOLIDATED STATEMENTS OF OPERATIONS 

(in thousands, except per share amounts)






Three Months Ended


March 31,


2013


2012

Product revenue

$           150,024


$           106,803

Service revenue

49,047


48,830

Total revenue

199,071


155,633





Cost of product revenue

105,533


72,326

Cost of service revenue

30,301


29,785

Total cost of revenue

135,834


102,111

Gross profit

63,237


53,522

% of revenues

31.8%


34.4%

Selling, general and administrative expenses

52,791


44,575

Bad debt expense

3,397


3,465

Acquisition and integration expenses

4,623


172

Restructuring and other expenses

1,278


387

Amortization of intangibles

2,082


879

Income from operations

(934)


4,044

Interest expense, net

6,478


6,569

Net income (loss) from continuing operations,  before income taxes

(7,412)


(2,525)

Tax provision (benefit)

58


(502)

Net income (loss) from continuing operations, net of income taxes

(7,470)


(2,023)

Net income (loss) from discontinued operations, net of income taxes

(658)


(680)

Net income (loss)

$             (8,128)


$             (2,703)





Basic weighted average shares

57,047


55,307

Diluted weighted average shares

57,047


55,307





Income (loss) per common share:




Basic loss from continuing operations

$               (0.13)


$               (0.04)

Basic income (loss) from discontinued operations

$               (0.01)


$               (0.01)

Basic income (loss)

$               (0.14)


$               (0.05)





Diluted loss from continuing operations

$               (0.13)


$               (0.04)

Diluted  income (loss) from discontinued operations

$               (0.01)


$               (0.01)

Diluted income (loss)

$               (0.14)


$               (0.05)


Schedule 3

BIOSCRIP, INC





CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)



Three Months Ended March 31,


2013


2012

Cash flows from operating activities:




Net income (loss)

$           (8,128)


$        (2,703)

Less: Income from discontinued operations, net of income taxes

(658)


(680)

Loss from continuing operations, net of income taxes

(7,470)


(2,023)

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:




Depreciation

2,459


1,931

Amortization of intangibles

2,082


879

Amortization of deferred financing costs

356


284

Change in deferred income tax

457


(300)

Compensation under stock-based compensation plans

1,973


966

Loss on disposal of fixed assets

13


23

Changes in assets and liabilities, net of acquired business:




Receivables, net of bad debt expense

(16,526)


(16,761)

Inventory

13,199


4,215

Prepaid expenses and other assets

4,787


4,238

Accounts payable

(2,822)


5,587

Claims payable

187


(6,598)

Amounts due to plan sponsors

(4,140)


(874)

Accrued expenses and other liabilities

(6,745)


4,557

Net cash provided by (used in) operating activities from continuing operations

$         (12,190)


$        (3,876)

Net cash provided by (used in) operating activities from discontinued operations

(658)


6,401

Net cash provided by (used in) operating activities

$         (12,848)


$          2,525

Cash flows from investing activities:




Purchases of property and equipment, net

$           (3,655)


$        (1,547)

Cash consideration paid for asset acquisitions

(72,325)


Cash consideration paid to DS Pharmacy


(2,935)

Cash consideration paid for unconsolidated affiliate, net of cash acquired

(900)


Net cash provided by (used in) investing activities from continuing operations

(76,880)


(4,482)

Net cash provided by (used in) investing activities from discontinued operations


2,741

Net cash used in investing activities

$         (76,880)


$        (1,741)

Cash flows from financing activities:




Borrowings on line of credit

214,145


481,151

Repayments on line of credit

(187,092)


(483,224)

Repayments of capital leases

(68)


(35)

Net proceeds from exercise of employee stock compensation plans

642


1,324

Net cash provided by (used in) financing activities from continuing operations

$          27,627


$           (784)

Net change in cash and cash equivalents

(62,101)


Cash and cash equivalents - beginning of period

62,101


Cash and cash equivalents - end of period






DISCLOSURE OF CASH FLOW INFORMATION:




Cash paid during the period for interest

$               322


$          1,241

Cash paid during the period for income taxes

$                  (6)


$             197

DISCLOSURE OF NON-CASH TRANSACTIONS:




Capital lease obligations incurred to acquire property and equipment


$               20

 

Schedule 4

BIOSCRIP, INC


Reconciliation between GAAP and Non-GAAP Measures

(in thousands)






Three Months Ended


March 31,


2013


2012

Results of Operations:




Revenue:




Infusion Services - product revenue

$         150,024


$        106,803

Infusion Services - service revenue

4,353


2,250

Total Infusion Services revenue

154,377


109,053





Home Health Services - service revenue

17,942


16,711

PBM Services - service revenue

26,752


29,868





Total revenue

$         199,071


$        155,632





Adjusted EBITDA by Segment before corporate overhead:




Infusion Services

$           12,315


$            7,783

Home Health Services

883


1,080

PBM Services

6,199


6,098

Total Segment Adjusted EBITDA

19,397


14,961





Corporate overhead

(7,916)


(6,582)

Consolidated Adjusted EBITDA

11,481


8,379





Interest expense, net

(6,478)


(6,569)

Income tax (expense) benefit

(58)


502

Depreciation

(2,459)


(1,931)

Amortization of intangibles

(2,082)


(879)

Stock-based compensation expense

(1,973)


(966)

Acquisition and integration expenses

(4,623)


(172)

Restructuring and other expenses

(1,278)


(387)

Net (loss) income:

$           (7,470)


$           (2,023)









Supplemental Operating Data








Total Assets




Infusion Services

$         523,857


$        438,623

    Home Health Services

63,280


62,403

PBM Services

30,909


36,354

Corporate unallocated

45,189


95,813

Assets from discontinued operations

-


-

Assets associated with discontinued operations, not sold

2,479


9,183

Total

$         665,714


$        642,376

 

BIOSCRIP, INC


Reconciliation between GAAP and Non-GAAP Earnings Per Share

(in thousands)




Three Months Ended




March 31,




2013 1,2


2012 3,4

Net income from continuing operations

$           (7,470)


$           (2,023)


Non-GAAP adjustments:






Restructuring and other expenses

1,278


308



Acquisition and integration expenses

4,623


137



Amortization of intangibles

2,082


699



Compensation under stock-based compensation plans

1,973


769

Non-GAAP net income from continuing operations

$            2,486


$              (110)













Earnings per share from continuing operations, basic and diluted

$             (0.13)


$             (0.04)


Non-GAAP adjustments:






Restructuring and other expenses

0.02


0.01



Acquisition and integration expenses

0.08


-



Amortization of intangibles

0.04


0.01



Compensation under stock-based compensation plans

0.03


0.02

Non-GAAP earnings per share from continuing operations, basic and diluted

$              0.04


$                  -







Weighted average shares outstanding, basic 

57,047


55,307

Weighted average shares outstanding, diluted

58,509


55,307

 

Schedule 4

BIOSCRIP, INC


Reconciliation between GAAP and Non-GAAP Earnings Per Share

(in thousands)



(1)

For the three months ended March 31, 2013 non-GAAP net income from continuing operations adjustments are net of tax, calculated using an annual effective tax rate offset by the effect of our net operating loss carryforwards.  The tax expense netted against restructuring and other expenses, acquisition and integration expenses, amortization of intangibles, and stock-based compensation expense was zero for each, respectively.


(2)

For the three months ended March 31, 2013, non-GAAP Adjusted EPS per basic and diluted share from continuing operations adjustments are net of tax, calculated using an annual effective tax rate method offset by the effect of our net operating loss carryforwards.  The tax expense per basic and diluted share netted against restructuring and other expenses, acquisition and integration expenses, amortization of intangibles, and stock-based compensation expense was $(0.00) per share, respectively.


(3)

For the three months ended March 31, 2012, non-GAAP net income from continuing operations adjustments are net of tax, calculated using an annual effective tax rate offset by the effect of our net operating loss carryforwards.  The tax expense netted against restructuring and other expenses, acquisition and integration expenses, amortization of intangibles, and stock-based compensation expense was $79, $35, $180 and $197 respectively.


(4)

For the three months ended March 31, 2012, non-GAAP Adjusted EPS per basic and diluted share from continuing operations adjustments are net of tax, calculated using an annual effective tax rate  offset by the effect of our net operating loss carryforwards.  The tax expense per basic and diluted share netted against restructuring and other expenses, acquisition and integration expenses, amortization of intangibles, and stock-based compensation expense was $(0.00) per share, respectively.

 

SOURCE BioScrip, Inc.



RELATED LINKS
http://www.bioscrip.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.